Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $21.07 Analyst target: $47.45 Upside: 125.20%
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The company is headquartered in Carlsbad, California.
See the full interactive analysis & chart →Informational only — not investment advice.